Clinical Trial Update: Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of gemcitabine, nab-paclitaxel, and KPT-330 in advanced pancreatic cancer completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acinar Cell Adenocarcinoma of the Pancreas
• Duct Cell Adenocarcinoma of the Pancreas
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• KPT-330
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Mohammed Najeeb Al Hallak | Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-11-07